Abstract
BACKGROUND Glioblastoma (GBM) is the most aggressive and lethal primary brain tumour, characterised by rapid proliferation, extensive migration, and resistance to therapies driven by stem-like GBM cells. Inflammatory pathways may play a critical role in modulating GBM migration and therapeutic resistance. The interleukin-33 (IL-33)/ST2 axis has garnered attention for activating downstream pathways that promote cell survival, growth, migration, and invasion. This study aims to explore the role of IL-33/ST2 signalling in GBM cell proliferation, migration, stemness, and treatment response, highlighting its potential contribution to GBM aggressiveness. MATERIAL AND METHODS The effects of IL-33 supplementation (5, 10, 20, and 50 ng/mL) on cell proliferation were evaluated in 2D (cell viability assay) and 3D (tumour spheroid) models in 4 patient-derived GBM stem cell lines (G7, E2, OX5-core, OX5-edge) cultured in stem cell-enriched conditions. Migration was assessed via wound healing and transwell assays. GBM-stem cell frequency was measured using a 3D extreme limiting dilution assay. IL-33, ST2, and γH2AX expression post-irradiation (0 and 2 Gy) were analysed by immunofluorescence to assess IL-33/ST2 axis responses to DNA damage. Statistical analysis was performed using unpaired t test or two-way ANOVA with appropriate post hoc tests, and ELDA software for stem cell frequency estimation. RESULTS IL-33 treatment significantly enhanced the migratory capacity of all four GBM cell lines in a concentration-dependent manner in wound healing assays, with 20 ng/mL exhibiting a 2.30(p≤0.01), 1.18(p≤0.01), 2.31(p≤0.0001), 1.75(p≤0.001) fold increase in G7, E2, OX5(core) and OX5(edge), respectively, compared to vehicle. This pro-migratory effect was further confirmed using Transwell assays, exhibiting a 1.84(p≤0.0001), 2.15(p≤0.0001), 5.14(p≤0.0001) and 1.22(p≤0.0001) fold in G7, E2, OX5(core) and OX5(edge) cells separately, treated with IL-33 compared to vehicle, suggesting a pro-migratory role of IL-33 in GBM. Under 2D or 3D conditions, IL-33 did not impact GBM cell proliferation or stemness. ST2 cytoplasmic expression in G7 GSCs was significantly increased (p≤0.01) following IR treatment, indicating that radiation may modulate IL-33/ST2 activity in GBM cells across the examined 24h time-course. However, no colocalisation was observed between IL-33, ST2 and γH2AX expression, suggesting spatial separation of IL-33/ST2 signalling from DNA damage response foci. CONCLUSION Our study provides novel insights into the role of the IL-33/ST2 axis in GBM progression, highlighting its ability to enhance cell migration while having minimal impact on proliferation and stemness. The modulation of ST2 expression following RT suggests that IL-33/ST2 axis may influence GBM responses to radiation, warranting further investigation into its role in radiation resistance.
| Original language | English |
|---|---|
| Pages (from-to) | iii130-iii130 |
| Number of pages | 1 |
| Journal | Neuro-Oncology |
| Volume | 27 |
| Issue number | Supplement_3 |
| DOIs | |
| Publication status | Published - 3 Oct 2025 |
| Event | 20th Meeting of the European Association of Neuro-Oncology - Prague, Czech Republic Duration: 16 Oct 2025 → 19 Oct 2025 https://www.eano.eu/eano2025/ |
Keywords
- signal transduction
- cell proliferation
- stem cells
- glioblastoma
- cell lines
- cell motility
- neoplasms